Description: Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Home Page: www.herontx.com
HRTX Technical Analysis
4242 Campus Point Court
San Diego,
CA
92121
United States
Phone:
858 251 4400
Officers
| Name | Title |
|---|---|
| Dr. Barry D. Quart Pharm.D. | Chairman & CEO |
| Mr. John W. Poyhonen | Pres & Chief Commercial Officer |
| Mr. David L. Szekeres | Exec. VP & COO |
| Ms. Lisa Peraza | VP & Chief Accounting Officer |
| Ms. Kimberly J. Manhard | Exec. VP of Drug Devel. & Director |
| Mr. Sean T. Ristine | Sr. VP of HR |
| Dr. Thomas B. Ottoboni Ph.D. | Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences |
| Mr. Michael E. Mathews | Sr. VP of Acute Care |
| Dr. Chris M. Storgard | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.8217 |
| Price-to-Sales TTM: | 3.072 |
| IPO Date: | 1987-08-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 302 |